Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing firstname.lastname@example.org or calling +44 (0)1707 367554.
Evaluating haemophilia A care
The theme for the 14th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) was Elevating haemophilia A care: where are we now and where are we heading?. Roche/Chugai sponsored posters included an evaluation of the economic burden of joint problems in people with haemophilia A and the low immunogenicity of HEMLIBRA (emicizumab). At the Virtual Roche Satellite Symposium, expert speakers put the unmet needs of patients in the spotlight. Find out more below.
Congress poster presentations from or supported by Roche/Chugai
Links to Roche/Chugai sponsored posters from the EAHAD Annual Meeting, held 3–5 February 2021.
141. Low immunogenicity of emicizumab in persons with haemophilia A
Schmitt C et al.
Video highlights from EAHAD 2021 Virtual Roche Satellite Symposium
When the video is playing on a desktop device, you can click the ☰ menu in the top left corner to access different chapters. Click again to hide the chapters menu
Haemophilia experts, Dr Charles Percy, Prof Cédric Hermans and Prof Gili Kenet talk through clinical and real-world data, to discuss the remaining unmet needs in patients with haemophilia A. They review how modern therapies can offer patient benefits, beyond bleed protection, and present two patient cases from their clinical experience. They then discuss what matters most to patients, as the focus now turns to quality of life, joint health, pain and treatment burden.
Dr Charles Percy, Haemophilia Centre Director at Queen Elizabeth Hospital, Birmingham
Dr Charles Percy is a consultant haematologist, haemophilia centre director and the clinical service lead for laboratory haematology at the Queen Elizabeth Hospital in Birmingham. He is currently chair of the Inhibitor Working Party of the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO).
Prof Cédric Hermans, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
Prof Cédric Hermans currently heads the Division of Haematology, the Haemostasis and Thrombosis Unit, and the Haemophilia Centre of the Saint-Luc University Hospital. He was president of EAHAD from 2016–2018 and is currently a member of the board of directors of the World Federation of Hemophilia (WFH), as well as being the editor-in-chief of Haemophilia journal.
Prof Gili Kenet, Sheba Medical Center, Tel Aviv University, Israel
Prof Gili Kenet is the director for the National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, and head of the Amalia Biron Thrombosis Research Institute at Tel Aviv University. She is an active member of International Society on Thrombosis and Haemostasis (ISTH) (previous chair of the Scientific and Standardisation Committee (SSC) of pediatric/perinatal hemostasis and co-chair of the SSC of FVIII/FIX and bleeding disorders), World Federation of Hemophilia (WFH), American Society of Hematology (ASH), an active reviewer for high impact thrombosis journals and an editorial board member of Haemophilia journal.
ASH, American Society of Hematology; EAHAD, European Association for Haemophilia and Allied Disorders; FVIII, Factor VIII; FIX, Factor IX; ISTH, International Society on Thrombosis and Haemostasis; SSC, Scientific and Standardisation Committee; WFH, World Federation of Hemophilia; UKHCDO, United Kingdom Haemophilia Centre Doctors’ Organisation.
- HEMLIBRA Summary of Product Characteristics.
Date of preparation: August 2021